Amarin: 3 Key Takeaways for Long-Term Investors

On its third-quarter 2026 earnings call, held on Oct. 28, 2026, Amarin (NASDAQ:AMRN) announced its return to profitability following corporate restructuring and reduced operating expenses. The cardiovascular drug maker generated $9 million in operating cash flow through its existing international distribution partnerships across Europe.

Three takeaways from management's comments highlight where the business is headed.

1. Cost Restructuring Drives Return to Profitability

Amarin reduced operating expenses nearly by half after streamlining its business. It generated $9 million in operating cash flow during the quarter, helping deliver $245,000 in net income despite price pressure from U.S. generic competitors.

We reported our first profitable quarter in two years, reflecting the benefits of our completed restructuring as well as our company-managed U.S. and fully partnered international commercial model.
-- Pete Fishman, Chief Financial Officer

2. International Partnerships Accelerate European Demand

Commercial partner Recordati expanded distribution of VAZKEPA, Amarin's prescription cardiovascular drug in Europe. That expansion drove an estimated 68% rise in European in-market demand year over year. Outsourcing overseas sales lets Amarin enter dozens of international markets without building costly local commercial teams.

Recordati has been an outstanding partner. While we're still in the early stages of the partnership, their execution and investment are driving momentum materially above historical European growth rates achieved by Amarin prior to the licensing transaction.
-- Aaron Berg, President and Chief Executive Officer

3. Clinical Data Opens Potential Oncology Applications

A phase III trial evaluated VASCEPA, Amarin's prescription omega-3 heart medication, in patients undergoing surgery for colorectal cancer liver metastases. The trial missed its primary endpoint measuring progression-free survival, but it showed a 32% lower hazard of death in overall survival.

A statistically significant 32% lower hazard of death, which is a meaningful finding in a patient population where up to 60% of patients may experience disease recurrence within two years following surgery.
-- Steve Ketchum, President of Research and Development and Chief Scientific Officer

Looking Ahead

Four consecutive quarters of positive cash flow and zero debt give Amarin stability as international demand expands. Global partner networks and patent protection through 2039 provide operational advantages as management monitors pricing discipline.

We enter the final quarter of 2026 from a position of strength, focused on sustaining positive cash generation, supporting our partners' growth, and building long-term shareholder value.
-- Aaron Berg, President and Chief Executive Officer

Working with financial advisor Barclays, leadership is evaluating options for capital deployment, including share repurchases.

In parallel, the progress we've made in reshaping Amarin has put us in a stronger position than at any point in our recent history to deliver value to our shareholders.
-- Aaron Berg, President and Chief Executive Officer

The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.